Page 31 - FLIPBOOK

GnRH antagonists cause significantly less cardiovascular adverse effects than the

more frequently used GnRH agonists.

▪ Review of 10 studies with GnRH

antagonists, degarelix (n = 1681) and

relugolix (n = 734) which were compared

with GnRH agonists (n = 1314).

▪ The pooled risk ratios (95% confidence

intervals) among GnRH antagonist

recipients for adverse cardiovascular

events, was 0.57 (0.39– 0.81).

Crine F. et al. Eur Hearth J Cardiovasc Pharmacoth, 2021 Jan 20;pvab005. doi: 10.1093/ehjcvp/pvab005